BrainStorm Cell Therapeutics Inc.
Tel Aviv
355 articles with BrainStorm Cell Therapeutics Inc.
-
BrainStorm Cell Therapeutics’ President and CEO to be Featured as Keynote Speaker at Cell Series UK 2019
10/24/2019
BrainStorm Cell Therapeutics Inc. announced, Chaim Lebovits, President and CEO, will serve as a Keynote Speaker at Cell Series UK.
-
BrainStorm Cell Therapeutics Presentations at Neuromuscular Drug Development Summit
10/23/2019
BrainStorm Cell Therapeutics Inc. will be participating and presenting scientific data at the upcoming Neuromuscular Drug Development Summit, from October 23-25th, in Boston MA. The Summit is dedicated to solving the challenges in developing second generation neuromuscular therapeutics..
-
BioSpace Movers & Shakers, Sept. 13
9/13/2019
Biotech and pharma companies strengthen their leadership teams with new appointments. -
FDA Accepts BrainStorm’s NurOwn® IND Application for Progressive Multiple Sclerosis U.S. Phase 2 Study to Begin in First Quarter of 2019
12/17/2018
BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of innovative autologous adult stem cell therapeutics for debilitating neurodegenerative diseases, today announced that the U.S. Food and Drug Administration (FDA) has accepted the Investigational New Drug (IND) application to initiate a Phase 2 clinical trial of NurOwn® for the treatment of progressive multiple sclerosis (MS).
-
BrainStorm Cell Therapeutics Announces Submission of IND for NurOwn® in Progressive Multiple Sclerosis
11/19/2018
BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of innovative autologous adult stem cell therapeutics for debilitating neurodegenerative diseases, today announced that it has submitted an Investigational New Drug (IND) application with the U.S. Food and Drug Administration (FDA) to initiate a Phase 2 study of NurOwn® in patients with progressive multiple sclerosis (MS).
-
Plenty of biotech companies will be releasing their third-quarter financial reports next week. Let’s take a quick look at some of these companies and their top stories they reported through 3Q2018.
-
BrainStorm Poster Receives Clinical Abstract Award at NEALS Conference
10/4/2018
BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of innovative autologous adult stem cell therapeutics for debilitating neurodegenerative diseases, announced today that their scientific abstract presented by Dr. James Berry entitled, “MicroRNA Changes in the NurOwn® Phase 2 ALS Randomized Clinical Trial: Relationship to Neuroprotection and Innate Immunity”,
-
BrainStorm Highlights Translational Data and Presentations Supporting NUROWN® Technology Platform as a Best-In-Class Strategy in ALSNurOwn® to be Featured at NEALS and Cell & Gene Meeting on the Mesa Conferences
10/3/2018
BrainStorm Cell Therapeutics Inc. announced today that members of its executive team will present at the Northeast Amyotrophic Lateral Sclerosis (NEALS) Conference in Clearwater, Florida and the Cell & Gene Meeting on the Mesa 2018 Conference in La Jolla, California, both taking place today, October 3, 2018.
-
Movers and Shakers for Sept. 10
9/10/2018
Let's take a look at who made a splash in the pharma and biotech world the past week. -
Privately-held ITF Pharma snagged regulatory approval for Tiglutik, a liquid formulation of riluzole for the treatment of amyotrophic lateral sclerosis.
-
ALS is a progressive neurodegenerative disease that affects neurons in the brain and the spinal cord. The disease is usually fatal within two to five years of diagnosis. While there is no cure for the disease, multiple companies are working on treatments hoping to be the first to provide a viable...
-
BrainStorm Announces Grant of a New European Patent for NurOwn®
7/25/2018
BrainStorm Cell Therapeutics Inc. announced that the European Patent Office ("EPO") has granted an European-wide patent entitled 'Mesenchymal Stem Cells for the Treatment of CNS Diseases' for the treatment of Amyotrophic Lateral Sclerosis (ALS) with NurOwn®.
-
BrainStorm to Announce Second Quarter Financial Results of 2018 and Provide a Corporate Update on Monday July 23
7/17/2018
Conference Call and Live Webcast at 8.30am ET
-
BrainStorm Granted Japanese Patent for NurOwn®
7/5/2018
BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell therapeutics for neurodegenerative diseases, today announced that it has received a Decision to Grant notice from the Japanese Patent Office ("JPO") to issue a patent entitled: "Methods of generating mesenchymal stem cells which secrete neurotrophic factors."
-
BrainStorm Announces Second U.S. Manufacturing Site for NurOwn® Production
7/2/2018
NurOwn® is the company's ongoing randomized, double-blind, multi-dose Phase 3 clinical trial in patients with amyotrophic lateral sclerosis
-
With the end of June, numerous biotechs shored up their boards of directors and other advisory boards with new members as the companies continued to shape their future strategies.
-
BrainStorm Strengthens Executive Management Team with the Appointment of Susan Ward, Ph.D. and Joseph Petroziello
6/28/2018
Susan Ward, Ph.D. (Pfizer) Appointed Head of Clinical Operations Joe Petroziello (Juno Therapeutics) Appointed VP of Scientific & Corporate Communications
-
The senior leadership team at Israel-based BrainStorm Cell Therapeutics, Inc. has changed with the appointments of two seasoned industry veterans Joseph Petroziello and Susan Ward.
-
Less than a week after floating the idea of offering its experimental ALS therapy NurOwn to patients under the recently-passed Right-to-Try legislation, Israel-based BrainStorm Cell Therapeutics has reversed course.
-
BrainStorm Considers Offering Experimental NurOwn to ALS Patients Under Right-to-Try for a Hefty ...
6/21/2018
The first company has provided a potential out-of-pocket price for patients who seek access through the recently passed federal Right-to-Try legislation and it’s not cheap.